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Autism spectrum disorder (ASD) affecting about 1% of all children is associated, in
addition to complex genetic factors, with a variety of prenatal, perinatal, and postnatal
etiologies. In addition, ASD is often an important clinical presentation of some well-known
genetic syndromes in human.We discuss these syndromes as well as the role of themore
important prenatal factors affecting the fetus throughout pregnancy which may also be
associated with ASD. Among the genetic disorders we find Fragile X, Rett syndrome,
tuberous sclerosis, Timothy syndrome, Phelan–McDermid syndrome, Hamartoma tumor
syndrome, Prader-Willi and Angelman syndromes, and a few others. Among thematernal
diseases in pregnancy associated with ASD are diabetes mellitus (PGDM and/or
GDM), some maternal autoimmune diseases like antiphospholipid syndrome (APLS)
with anti-β2GP1 IgG antibodies and thyroid disease with anti-thyroid peroxidase (TPO)
antibodies, preeclampsia and some other autoimmune diseases with IgG antibodies that
might affect fetal brain development. Other related factors are maternal infections (rubella
and CMV with fetal brain injuries, and possibly Influenza with fever), prolonged fever and
maternal inflammation, especially with changes in a variety of inflammatory cytokines and
antibodies that cross the placenta and affect the fetal brain. Among the drugs are valproic
acid, thalidomide, misoprostol, and possibly SSRIs. β2-adrenergic receptor agonists and
paracetamol have also lately been associated with increased rate of ASD but the data is
too preliminary and inconclusive. Associations were also described with ethanol, cocaine,
and possibly heavy metals, heavy smoking, and folic acid deficiency. Recent studies
show that heavy exposure to pesticides and air pollution, especially particulate matter
<2.5 and 10µm in diameter (PM2.5 and PM10) during pregnancy is also associated
with ASD. Finally, we have to remember that many of the associations mentioned in this
review are only partially proven, and not all are “clean” of different confounding factors.
The associations described in this review emphasize again how little we know about the
etiology and pathogenesis of ASD. It is obvious that we need more epidemiologic data
to establish many of these associations, but if proven, they might be promising avenues
for prevention.
Keywords: ASD, genetic syndromes, autoimmune diseases, prenatal factors, inflammation, drugs, chemicals,
pollution
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INTRODUCTION
ASD is defined by the DSM 5 as a neurobehavioral disorder
manifested by persistent deficits in social and communication
interaction, deficits in developing, understanding and
maintaining relationships, as well as abnormal and fixed
interests and repetitive behavior (Kogan et al., 2009; American
Psychiatric Association, 2013). Symptoms must be present at
early childhood and interfere with daily function. ASD is 4 times
more prevalent in males than in females, but in experimental
animal models where ASD is induced by neuro-teratogens, there
are little gender differences. Mental impairment is common
among children with ASD, and a variety of learning and
behavioral changes are also prominent in autistic animals. The
etiology is diverse, largely unknown, and seems to be the result
of genetic and environmental interaction (Kogan et al., 2009;
Tchaconas and Adesman, 2013).
Environmental exposures are increasingly being recognized
as potential risk factors for ASD, and the possibility that the
prenatal and perinatal environment affect fetal programming
is an expanding direction for research. Prenatal environment
include maternal use of medication, maternal infection and
inflammations, and prenatal or perinatal exposure to various
substances such as alcohol and heavy air pollution. Of special
relevance are prematurity and maternal diabetes.
Epidemiology
The reported prevalence of autism has increased dramatically
over time, from 4 to 5 cases per 10,000 in 1966 to ∼1%
today (Kogan et al., 2009; Tchaconas and Adesman, 2013). The
increase is thought to result increased public awareness, changing
diagnostic standards, earlier age of diagnosis, and development of
treatment modes. It was also shown that many of the children
and adults who were previously diagnosed as having mental
retardation meet the DSM 4 and DSM 5 diagnostic criteria of
ASD (Shattuck, 2006; Elsabbagh et al., 2012). Some increase,
however, may result from “new” environmental causes such as
pollution and changing life style.
In the US, for example, the autism and developmental
disabilities monitoring network (ADDM network) found in
children aged 8 years in 2008 an increase from 1/150 in year
2000 to 1/88 in 2008 and in the 2010 monitoring the rate
increased to 1/68 children (Autism Developmental Disabilities
Monitoring Network Surveillance Year Principal Centers for
Disease Prevention, 2012).
In Israel, judging from the number of children who received
childhood disability benefits by the Israeli Insurance Institute
because of ASD, the cumulative incidence at 8 years of age at 2011
has increased 10-folds from 1991 and reached 0.49% with a ratio
of males/females of about 5 (Raz et al., 2015b).
The more recent global prevalence of autism was estimated
to be 0.62% (Autism Developmental Disabilities Monitoring
Network Surveillance Year Principal Centers for Disease
Prevention, 2012; Elsabbagh et al., 2012). In spite of a wide
variation in prevalence between the studies, the authors conclude
that there is no evidence of a significant impact of ethnic or
socioeconomic factors on the rate of ASD.
It can be presumed that in developed countries the great
progress in the diagnosis and treatment of ASD reached a
relatively steady state at least in the last 10 years. However, both
the incidence and prevalence of ASD continued to rise, implying
that some of the increase results from a true increase in ASD
rate. For example, in the UK in 1988–92 the incidence was
0.40/10,000 person years and it raised to 2.98/10,000 person years
in 2000–2001 (Smeeth et al., 2004) and an in the US an increase
was reported in the same states in the US between 2000 and
2008 and a further increase between 2008 and 2010 (Fombonne,
2009; Autism Developmental Disabilities Monitoring Network
Surveillance Year Principal Centers for Disease Prevention,
2012). An increased incidence was also reported in Israel
(Davidovitch et al., 2013). If this is correct, it may largely
result from prenatal environmental causes because genetic,
ethnic, socioeconomic, and geographic factors did not change
significantly during that time. Recent meta-analysis of seven
studies including 1,140,210 children evaluated the association
between inter-pregnancy interval and increased risk of ASD,
and found OR of 1.9 for interval <12 months and 1.37 interval
>5 years. Proposed mechanisms included folate deficiency,
maternal stress, and sustained post-partum inflammation from
previous pregnancy for short interval and infertility, unintended
pregnancy, and inflammation for long one (Conde-Agudelo et al.,
2016). Genetic predisposition was offered by Darbro et al. who
found decreased risk of cancer among ASD patients. Despite
increased prevalence of rare coding single-nucleotide variations
in oncogenes they tend to develop fewer neoplasms. They
hypothesized that the protective effect may be due to defects in
cellular proliferation and aging (Darbro et al., 2016).
The prenatal causes of ASD can be divided into environmental
chemicals (i.e., drugs such as valproic acid, thalidomide,
misoprostol; alcohol, cocaine, and toxic metals taken by the
mother during pregnancy), exposure to particulate matter air
pollution of up to 2.5 micron in diameter (PM2.5), maternal
infections during pregnancy (i.e., rubella, CMV), maternal and
fetal inflammation (Fox et al., 2012) and maternal diseases (i.e.,
diabetes mellitus), including autoimmune diseases (Brown et al.,
2015) or allergic diseases such as asthma (Croen et al., 2005).
In addition, perinatal factors such as perinatal asphyxia, IUGR,
RDS, and others were also associated with an increase in the
prevalence of ASD (Gardener et al., 2011).
Numerous mechanisms for ASD have been offered, based
also on experimental animal models. In addition to complex
genetic susceptibility, epigenetic changes have also been
proposed (Kogan et al., 2009). Other mechanisms are: immune
dysregulation that include abnormal levels of cytokines and
growth factors and various fetal and maternal antibodies to
brain tissue (Rossignol and Frye, 2012). Additional proposed
mechanisms are increased oxidative stress, mitochondrial
dysfunction, abnormalities in brain serotonin, abnormal white
matter connectivity, decrease number of Purkinje cells in the
cerebellum, and neuronal migration defects (Billeci et al., 2012;
Grabrucker, 2012; Rossignol and Frye, 2012).
The purpose of the present review is to summarize the data
describing genetic syndromes with ASD like behavior and the
maternal diseases associated with increased prevalence of ASD.
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In addition, we summarize the antenatal injurious factors that are
known to be related to the etiology and pathogenesis of ASD.
GENETIC SYNDROMES ASSOCIATED
WITH OR PREDISPOSING TO ASD
ASD phenomenology varies between syndromes, but in some
it is more common than in the general population (Richards
et al., 2015). Several human syndromes derived from a
single gene mutation increase the risk for ASD. The more
common aberrations are Fragile X syndrome, a mutation
in FMR1 (Kaiser-McCaw et al., 1980), Rett syndrome, a
mutation in MECP2 (Meloni et al., 2000), tuberous sclerosis,
mutations in TSC1 or TSC2 (Green et al., 1994), Timothy
syndrome, a mutation in CACNA1C (Gillis et al., 2012),
and Hamartoma tumor syndrome, a mutation of the PTEN
gene. Copy-number variants that lead to inherited maternal
15q11–13 duplication resulting in Prader-Willi and Angelman
syndromes (Ogata et al., 2014) and other duplications like
the NPHP1 gene (Yasuda et al., 2014) are also associated
with autistic traits. Patients with other syndromes like 22q.11.2
deletion—DiGeorge syndrome (Swillen andMcDonald-McGinn,
2015) and neurofibromatosis type 1 (Huijbregts et al., 2015)
show behavioral changes that are also common among ASD
patients. Multiple other syndromes were associated with ASD,
however cases are sporadic (Moss and Howlin, 2009). The
development in strategies for the identification of genetic
variants led to the description of new syndromic forms of ASD
and enabled the association between phenotype and genetic
traits.
Fragile X (FMR1)
Children with Fragile X syndrome which is the most frequent
inherited cause of mental retardation have increased rates of
ASD. Current estimates suggest that ASD occurs in 21–50%
of males with fragile X syndrome, with increased prevalence
among individuals with a greater degree of intellectual disability
(Moss and Howlin, 2009; Wadell et al., 2013). The Fragile
Mental Retardation 1 locus (FMR1) resides in the X chromosome
and expansion of triplet repeats in the untranslated region
of the FMR1 gene prevents synthesis of the FMR1 gene
product FMRP. FMRP is a RNA-binding protein that modulates
mRNA trafficking, dendritic maturation and synaptic plasticity.
FMRP deficiency leads to dysregulation of other pathways
including metabotropic glutamate receptors (mGluR1 and 5),
aminobutyric acid A and B pathways, phosphatidylinositol 3-
kinase, and mammalian target of rapamycin pathways. FMRP
regulates proteins known to be mutated in autism including
neuroligins, neurorexins, SHANK, phosphatase, and tensin
homolog (Darnell et al., 2011). Deficits in global network
organization and decreased clustering with connectome that
shift toward randomness were found by Bruno et al among
fragile X patients by structural brain network topology evaluation
with magnetic resonance imaging (MRI), a finding that was
qualitatively similar to what has been described in ASD (Bruno
et al., 2016). When 47 children and adolescents with fragile
X were assessed for ASD symptoms, most were engaged in
self injury behavior, aggression, and stereotypy (Newman et al.,
2015). Compared to children with fragile X, those who also had
ASD developed slower, had lower developmental level for age
that improved over time and performed worse at language tasks
(Ballantyne and Nunez, 2016). Boys with fragile X were found to
have social smiling less impaired and complex mannerisms more
impaired compared to boys with non-syndromic ASD (McDuffie
et al., 2015). Besides behavioral Interventions that were proven
beneficial, medical therapy based on the pathophysiology of
fragile X is currently investigated (Newman et al., 2015). Waddell
et al revised the medical treatment modalities based on the up-
regulation of the metabotropic glutamate receptor 5 (mGluR5)
pathway and down-regulation of the GABA A pathway. The
mGluR5 antagonists evaluated in human studies, Fenobam and
AFQ056, improved behavior. The GABA B agonist Arbaclofen
which is the R-isomer of baclofen and a GABA B agonist that
works at a presynaptic receptor improved social behavior of
patients with fragile X and ASD. Minocycline, which lowers
the levels of matrix metalloproteinase 9 (MMP9), one of a
family of proteins important for synaptic plasticity, improved
language and behavior among adolescents and young adults with
fragile X, however minocycline may cause in young children
graying of the permanent teeth when they emerge (Wadell
et al., 2013). Human studies with antioxidants like melatonin
(Karaaslan and Suzen, 2015; Kwon et al., 2015) and omega 3
fatty acid, vitamin C, vitamin E, and N acetyl cysteine have
been tried in single cases. Acetylcarnitine (LAC) was proven
beneficial among fragile x patients with ADHD (Wadell et al.,
2013).
Rett Syndrome and MECP2 Mutations
Rett syndrome, an X linked disease that affects girls, is
characterized by neurodevelopmental delay, ASD and seizures.
Estimates of rates of ASD in Rett syndrome range from 25
to 40% and up to 97% in individuals with the preserved
speech variant of Rett syndrome (Moss and Howlin, 2009). It
is caused by mutations in the gene encoding for the methyl-
CpG binding protein 2 (MeCP2) that binds to methylated-
CpG dinucleotides and influences gene expression. MeCP2 is
expressed widely, but is most abundant in neurons of the mature
nervous system. MeCP2 duplication syndrome is characterized
by autism, intellectual disability, motor dysfunction, anxiety,
epilepsy, recurrent respiratory tract infections and early death.
The MET receptor tyrosine kinase gene which is a part of
the biological network that includes several ASD-associated
transcriptional regulators, including FOXP2 and MeCP2 was
found reduced in the temporal lobe of subjects with ASD.
Regulation of MET transcription by MeCP2 was found in vitro
in primary human neural progenitors from the olfactory
epithelium. Analyses of postmortem temporal cortex samples
from Rett syndrome and ASD cases demonstrated sex-based
differences in reduced MET expression, with males’ perturbation
in ASD and females in Rett syndrome (Plummer et al., 2013).
In a UK national sample of 91 women with Rett syndrome
aged from 4 to 47 years behavioral disturbances included hand
stereotypies (99%), low mood/changeable mood (77%), anxiety
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or inappropriate fear (73%), sleeping difficulties and night-
time laughing (64%), teeth grinding (58%), and breath holding
(63%) (Cianfaglione et al., 2015). Despite autistic traits Rett
syndrome patients have some phenotypic features that differ
from ASD patients like increased visual fixation at social stimuli
(Schwartzman et al., 2015). Rett patients exhibited a decrease in
visual evoked potential (VEP) amplitude that was most striking
in the later stages of the disorder and a slower recovery from
the peak of the VEP response that was impacted by MeCP2
mutation type (Leblanc et al., 2015). Based on animal studies
in which IGF-1 and BDNF supplementation therapies improved
neuronal developmental, synaptic maturation and plasticity
exerted through the key cell-signaling pathways, PI3K/Akt and
MAPK inMeCP2mutant mice (Castro et al., 2013), a clinical trial
in 10 Rett syndrome patients showed improvement in social and
cognitive ability with recombinant human Insulin-Like Growth
Factor 1 supplementation (Pini et al., 2016).
Tuberous Sclerosis TSC1 or TSC2
Tuberous sclerosis complex is an autosomal dominant disorder
caused by mutations in either the TSC1 or TSC2 gene. The
syndrome is associated with cerebral cortical tubers and may be
complicated by astrocytomas. About 90% suffer from behavioral,
intellectual, psychiatric and psychosocial difficulties and up
to 60% have the diagnosis of ASD. There is disagreement
regarding the association of ASD with the presence of temporal-
lobe tubers (Moss and Howlin, 2009). The protein products
of TSC1, hamartin and TSC2, tuberin, inhibit Ras homolog
enriched in the brain (Rheb) that activates mammalian target
of rapamycin (mTOR) complex 1 (mTORC1). Heterozygous
defects in either TSC gene prevents the Rheb inhibition
and allows for excessive mTOR activation, which induce cell
growth and proliferation. Upregulation of the mTOR pathway
leads to abnormal dendritic protein synthesis with reduced or
dysmorphic dendritic spines and alterations in postsynaptic
glutamate receptor-mediated long-term depression, similar to
synaptic abnormalities described in ASD. Owing to the presence
of cardiac rhabdomyomas being detected by pre/perinatal
ultrasonography patients are diagnosed early, allowing prompt
detection of ASD symptoms (Davis et al., 2015). In a recent
study evaluating 42 patients aged 4–44 years that were diagnosed
with Tuberous sclerosis 17 (40%) had ASD that worsened with
intellectual disabilities. None of the patients with normal or
borderline mental abilities had ASD. The Social Communication
Questionnaire (SQL) score was positively associated with
epilepsy, seizure onset before age 1 year, infantile spasms and
mutations in TSC2, but not tubers localization and gender
(Vignoli et al., 2015). The mTOR inhibitors used in treatment of
TSC patients for various manifestations were also evaluated for
ASD symptoms. Clinical trials with Rapamycin supplementation
were inconclusive, some due to the severe intellectual deficits of
the evaluated patients. TSC patients with infantile spasms had
higher response rates compare to other patients when treated
with Vigabatrin which increase GABA availability in the synaptic
cleft. It is hypothesized that it may be associated with mTOR
suppression found in a murine model (Davis et al., 2015)
Timothy Syndrome—CACNA1C Mutation
Timothy syndrome (TS) is a rare dysmorphic disease presenting
with cardiac arrhythmias, syndactyly; immune deficiency,
intermittent hypoglycemia and neurologic morbidities including
seizures, mental retardation, and autism. It is a single nucleotide
mutation in the gene encoding the pore-forming subunits of
an L-type calcium channel (CaV1.2). The sporadic glycine-
to-arginine mutation is located at position 406 in exon 8A
(Splawski’s terminology). Both variants of TS (the milder TS1
and the more severe TS2) arise from missense mutations
in alternatively spliced exons that cause the same G406R
replacement in the CaV1.2 L-type calcium channel. Association
between non-syndromatic ASD and two SNPs in CACNA1C
was found in families of Chinese Han ancestry (Li et al., 2015).
Currently there is no specific treatment for ASD in patients
with Timothy syndrome. Mexiletine, a voltage-gated sodium
channel blocker improved cardiac symptoms in a 2 years old girl;
however no data concerning her psychological situation is given
(Gao et al., 2013).
Phelan–McDermid Syndrome—SHANK3
Deletion
Deletion of the human SHANK3 gene near the terminus of
chromosome 22q13 is associated with Phelan–McDermid
syndrome and autism. Clinical manifestations include
dysmorphic face with wide nasal bridge, pointed chin, deep-set
eyes, flat mid-face, large ears, long eyelashes, bulbous nose
and high-arched palate, hypotonia, developmental delay, and
delayed or absent speech. SHANK genes code for large synaptic
scaffold proteins of the post-synaptic density. SHANK deletions
or mutations were found in about 1% of cases of ASD. Among
760 ASD patients evaluated SHANK1 mutations were found in
0.04% and were present in males with normal IQ and autism,
SHANK2 mutations were present in 0.17% of patients with ASD
and mild intellectual disability and mutations in SHANK3 were
present in 0.69% of the patients with ASD. Those with SHANK3
deletions presented manifestations of the Phelan–McDermid
syndrome (Leblond et al., 2014). Using functional MRI to
evaluate neural response to communicative vocal sounds, infants
with Phelan–McDermid syndrome differed from infants with
ASD by their better neural response to communicative vocal
sounds in the right superior temporal gyrus (Wang et al., 2016).
Children with Phelan–McDermid syndrome were found to
have less sensory sensitivity as compared to children with ASD
(Mieses et al., 2016).
Hamartoma Tumor Syndrome—PTEN
Mutation
Phosphatase and tensin homolog on chromosome 10 (PTEN)
is a tumor suppressor gene that has been reported in autistic
individuals with macrocephaly, and also in some syndromes
including the Hippocampus Cowdon, the Lhermitte-Duclos
disease, and the Bannayan Riley Ruvalcaba Syndrome. More
recently, the term PTEN Hamartoma Tumor Syndrome (PHTS)
has been used to encompass the range of symptoms identified
in PTEN mutation carriers (Leslie and Longy, 2016). McBride
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et al found in their ASD cohort that 7/99 (7.1%) of the ASD
patients and 8/100 (8.0%) of those with mental retardation or
developmental delay had PTEN mutations, all of them also had
macrocephaly (McBride et al., 2010).
CNTNAP2 Mutations
The CNTNAP2 gene is located in chromosomal region 7q35. A
recessive nonsense mutation in the contactin associated protein-
like 2 (CNTNAP2) gene was shown to cause a syndromic
form of ASD, cortical dysplasia and focal epilepsy syndrome
(CDFE). This is a rare disorder resulting in epileptic seizures,
language regression, intellectual disability, hyperactivity, and
ASD. Neuronal migration defects were found in about half of
the patients (Strauss et al., 2006). The CNTNAP2 variant that
increases risk for the language impairments in autism was shown
to lead to abnormal functional brain connectivity in human
subjects (Scott-Van Zeeland et al., 2010). Besides ASD, mutations
in the CNTNAP2 gene were also found among patients with
Gilles de la Tourette syndrome, ADHD, language disturbances,
epilepsy, and schizophrenia (Poot, 2015).
15q11-13 Deletion or Duplication
Maternal/Paternal
Mutations in 15q11-13 are associated with either duplication
or gene deletion. Prader-Willi syndrome results from the loss
of imprinted genomic material within the paternal 15q11.2-13
locus and deletions, unbalanced translocations, or uniparental
maternal disomy. The loss of maternal genomic material at the
15q11.2-13 locus results in Angelman syndrome since normally,
only the maternal copy of the Ube3A gene is active in the
brain (Lasalle et al., 2015). Region duplications are the most
frequent genetic abnormality in autism and the penetrance rate in
individuals with a maternally derived duplication is>85% (Cook
and Scherer, 2008). Maternally inherited 15q11-13 duplications
and triplications are among the most common genomic copy
number variants identified in patients with autism. The dosage
of an imprinted gene or genes within the duplicated region
underlies the autism risk in these patients. E3 ubiquitin-protein
ligase, Ube3a is the only gene within the 15q11-13 duplicated
segment consistently expressed solely from the maternal allele
in mature neurons, and inactivating mutations or deletions
of Ube3a cause Angelman syndrome. Treatment attempts to
hypermethylate the maternal locus by using pro-methylation oral
supplements with folic acid and betaine (Peters et al., 2010) or
L-5-methyltetrahydrofolate, vitamin B12, betaine, and creatine
(Bird et al., 2011) failed to improve biochemical or behavioral
parameters.
Oxytocin (OXT Gene)
Oxytocin is a hormone known for its role in childbirth and
lactation. It is synthesized in neurons in the paraventricular
and supraoptic nuclei of the hypothalamus and transported
via axonal processing to the posterior pituitary, where it is
stored in secretory vesicles for release into the portal vascular
system to affect target organs, mainly the uterine and mammary
glands. Additionally, oxytocin neurons directly project from the
hypothalamus to the forebrain, the amygdala, the hippocampus,
and the nucleus accumbens. Recent publications showed its role
in interpersonal bonding behaviors and psychiatric disorders
(Kirsch, 2015). The oxytocin receptor gene is a neuropeptide that
contains many single-nucleotide polymorphisms (SNPs) with
inconsistency in the effect of these variants on ASD. LoParo
et al. revised data from eight studies evaluating 16 SNPs in
oxytocin receptor using data from 3941 individuals with ASD
from 11 independent samples and found significant associations
between ASD and the SNPs rs7632287, rs237887, rs2268491,
and rs2254298 (Loparo and Waldman, 2015). Another meta-
analysis which also included data bases from Germany found
an association with rs237889-A (Kranz et al., 2016). Studies on
plasma oxytocin concentrations in children with ASD reported
conflicting results, either lower levels (Modahl et al., 1998) or
without significant difference to healthy controls (Taurines et al.,
2014). Recently Francis et al showed association between OXT
rs6084258 and ASD (Francis et al., 2016). Despite no difference
between ASD children and controls, higher oxytocin blood levels
were found in girls, and were associated with anxiety among
the girls and less language impairment in the boys and girls
of both groups (Miller et al., 2013). The validity of plasma
oxytocin as a potential marker for brain levels was not evaluated
among ASD patients, however, blood and CSF levels among
non-psychiatric patients undergoing spinal anesthesia for minor
procedures failed to show correlation between blood and CSF
levels (Kagerbauer et al., 2013).
Oxytocin supplementation can be given either intravenously
or intranasal with intranasal being superior due to its being
well tolerated and easy to use. Reduction in repetitive
behaviors (Hollander et al., 2003) and improved affective speech
comprehension (Hollander et al., 2007) were found in ASD
adults following oxytocin infusion. Studies evaluating ASD
patients showed tasks improvement following a single dose
(Aoki et al., 2015). However, some failed to show treatment
effects (Althaus et al., 2015). Recent studies used continuous
administration in order to evaluate treatment effects on daily
life. Continuous intranasal administration over 6-weeks reduced
autism core symptoms specific to social reciprocity among adults
(Watanabe et al., 2015). Another study that failed to show
improvement in social cognition and repetitive behaviors after 6
weeks of treatment found improvements in measures of social
cognition and quality of life (Anagnostou et al., 2012). In a
double-blind, randomized, placebo-controlled, crossover clinical
trial, children with ASD at the age 3–8 years showed global
improvement and significant improvement in caregiver-rated
social responsiveness following a 5 week course of oxytocin
(Yatawara et al., 2015).
The possible role of oxytocin in the etiology of ASD, and
its potential use for the improvement of symptoms, is not yet
understood and needs more studies.
MATERNAL DISEASES AND ASD IN THE
OFFSPRING
Diabetes, several autoimmune diseases, infections and
inflammatory diseases during pregnancy have been
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associated with an increased rate of ASD in the offspring.
These diseases may apparently occur at any time during
pregnancy.
ASD in Offspring of Diabetic Mothers
Diabetic pregnancies, both pregestational diabetes (PGD) and
gestational diabetes (GD) are associated with a large number of
pregnancy complications. While PGD may increase the rate of
congenital anomalies in the offspring and affect fetal well-being
and growth, GD is mainly associated with disturbed fetal growth
and increased rate of a variety of pregnancy complications. Both
PGD and GD are associated with slight disturbances in postnatal
growth and development, also affecting fine and gross motor
development and increasing the rate of learning difficulties and
Attention Deficit Hyperactivity Disorder (Ornoy et al., 2001).
Both also seem to be associated with a slight but significant
increase in the rate of ASD in the offspring (Ornoy et al., 2015a).
Most, but not all studies on the possible association of
maternal diabetes and ASD show an increased rate, and only
recently is the type of diabetes in the mother (T1DM or T2DM or
GDM) in relation to ASD in the offspring being considered. Lyall
et al. (2012) assessed the possible association of maternal diabetes
and ASD in 793 children with ASD from a cohort of 66,445
pregnancies. The highest association was found with maternal
GD, as the OR of ASD among children born to mothers with
GD was 1.76. This is in slight contrast to other studies which
found that the risk for ASD is higher among offspring of mothers
with PGD compared to mothers with GDM. Gardener et al.
(2009) assessed the possible association of a variety of antenatal
maternal factors with ASD in the offspring. Maternal diabetes
was among the leading factors associated with ASD, with an odds
ratio of 2.07 (95% CI 1.24–3.47). In a very recent study by Li et al.
(2016) using the Boston Birth Cohort, both maternal diabetes
and pregestational obesity were highly associated with ASD in
the offspring. In mothers with PGD and obesity, the hazard ratio
(HR) for ASD was 3.91 (95% CI 1.76–8.68) and in obesity and
GD the HR was 3.04 (95% CI 1.21–7.63). As cohort and case-
control studies are being published, there appears to be a more
significant trend toward an association with ASD (Krakowiak
et al., 2012). However, there are also studies that could not
demonstrate such associations. For example, Hultman et al.
(2002) in their case control study on 408 Swedish children with
ASD compared to 2040matched controls, found an association of
ASD with a variety of pregnancy associated factors but not with
maternal diabetes. Xiang et al. (2015) found in a recent study on
pregnant women with preexisting type 2 diabetes. They found an
adjusted odds ratio for ASD incidence in the offspring of only
1.21, that was insignificant, but in the offspring of women with
GD diagnosed before the 26th week of pregnancy the HR was
significant—1.42 (95% CI 1.15–1.74). Guinchat et al. (2012) in
their review of 85 studies on the possible association between
prenatal, perinatal and neonatal factors and ASD did not find
a strong association of maternal diabetes and ASD. In contrast
to this review, Xu et al. (2014) culled from 167 publications
twelve; three cohort and nine case control studies. For the cohort
studies, the pooled risk of maternal diabetes was 1.48 (1.25–1.75,
p < 0.001), and for the case-control studies, the pooled odds ratio
was 1.72 (1.24–2.41, p = 0.001). The OR for offspring of mothers
with GD was generally lower than for that of mothers with PGD.
In a very recent study looking at the neuropsychiatric
morbidity in offspring of 12,642 women with gestational diabetes
compared to 218,629 non-diabetic women the investigators
found an adjusted odds ratio of 4.4 (95% confidence interval:
1.55–12.69) for ASD. They examined children born during 1991–
2014, and excluded prematurity, congenital anomalies, offspring
of mothers with pregestational diabetes and other possible
etiologic factors (Nahum Sacks et al., 2016).
The mechanism of the association between diabetes and ASD
is largely unknown. We should remember that the increased risk
found may be related to a variety of pregnancy complications
that are common in diabetes, or to effects on fetal growth
rather than to complications of hyperglycemia. Judging from
the proposed mechanisms of the effects of maternal diabetes
on the embryo and fetus, the increase in the rate of ASD in
diabetic pregnancies may result from increased fetal oxidative
stress, from epigenetic changes in the expression of several genes
and it may also be related to the other neurodevelopmental
changes induced by maternal diabetes (Ornoy et al., 2015b). It
was shown repeatedly that good control of diabetes in pregnancy
may reduce the different diabetic complications, but apparently
will not completely prevent them. Hence, this is probably also the
best way to reduce the diabetic—related ASD. There seem to be
no studies relating the prevalence of ASD to the degree of diabetic
control.
Maternal Autoimmune Diseases
In utero exposure to maternal antibodies and cytokines are
known potential risk factors for ASD. Recent studies associated
familial autoimmune diseases with the development of ASD.
Most results come from cohort studies. However, due to
the limited number of infants with ASD born to mothers
with autoimmune diseases, many studies are small. Three
Swedish registries including 1227 children with ASD [childhood
autism, Asperger syndrome, or pervasive developmental disorder
(PDD)] and 30,693 matched controls (25 controls for each
case) evaluated linkage for 19 parental autoimmune disorders
and found them weakly associated (maternal OR = 1.6,
paternal OR = 1.4). A positive history of rheumatic fever
was increased in both parents of ASD children, while type 1
diabetes, idiopathic thrombocytopenic purpura and myasthenia
gravis were increased only among mothers (Keil et al., 2010).
Out of 689,196 children born in Denmark from 1993 through
2004, a total of 3325 children were diagnosed with ASD. ASD
diagnoses included infantile autism (1089 children), atypical
autism, Asperger syndrome, and PDD. Children were evaluated
for parental autoimmune diseases diagnosed before pregnancy.
Increased ASD risk was found in offspring of families with
type 1 diabetes, offspring of fathers with endocrine autoimmune
diseases and mothers with rheumatoid arthritis and celiac
disease. Thyrotoxicosis in the family and the mother, specifically,
were related to lower risk of ASD (Atladottir et al., 2009).
Studies on the inter-relation of maternal autoimmune
disorders with ASD also showed increased susceptibility to ASD
among the offspring. A population-based cohort of 719 children
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born to 509 mothers with SLE, and a matched control group
of 8493 children born to 5824 mothers without SLE found that
children born to women with SLE had 1.4% recorded ASD
diagnoses compared to 0.6% among the controls (OR 2.25).
However, the numbers were small with 10 children of mothers
with SLE and 53 children of controls. In addition tomaternal SLE,
other potential predictors of ASD in the adjusted multivariate
analysis were gestational diabetes and male sex (Vinet et al.,
2015). The association between maternal autoimmune thyroid
disease and childhood autism was evaluated in 1.2 million
singleton births with 1132 cases of childhood autism (not
including Asperger disorder or PDD) in the Finnish cohort.
The cases were matched 1:1 to comparison subjects drawn
from the birth cohort who were without ASD. The odds of
childhood autism were increased by nearly 80% among offspring
of mothers who were positive for anti thyroperoxidase antibodies
(TPO-Ab+) during pregnancy, compared to mothers negative
for this autoantibody. The association was similar in males and
females. There were no associations between maternal clinical or
subclinical hypothyroidism or hyperthyroidism, maternal TSH
or free T4 and autism (Brown et al., 2015). A follow-up study
of 23 mothers with antiphospholipid syndrome (APLS) and their
36 children, and nine SLE mothers with 12 children revealed
ASD in 3 children of the APLS mothers. Four children of the
APLS mothers, of them the 3 ASD children had persistent anti-
β2GP1 IgG antibodies. None of the offspring of the SLE mothers
had either neurodevelopmental disorders or anti-β2GP1 IgG
antibodies. The ASD cases born to mothers with APLS had
normal birth weight, and normal genetic and metabolic work-
up. Cerebral MRI performed at the ages of 2.5, 2.6, and 3.4 years
were normal in two cases and revealed punctuate hyperintensities
in the white matter of one case. None of the children
had thrombosis or other antiphospholipid symptomatology
(Abisror et al., 2013).
A prospective follow-up of a European multicenter cohort
evaluated the long-term outcome and immunological status of
children born to mothers with APLS at 3, 9, 24 months and 5
years. Of 134 children, four displayed behavioral abnormalities,
which consisted with: autism (1), hyperactive behavior (1),
feeding disorder with language delay (1), and axial hypotonicity
with psychomotor delay (1). It is noteworthy that the mother
of the ASD offspring also suffered from gestational diabetes
(Mekinian et al., 2013).
Two large meta-analyses published lately found a significant
increase in ASD prevalence among children born to parents
with autoimmune diseases. Chen et al. evaluated nine case-
control studies and one cohort study published from 1999
to 2015 and comprising of 9775 ASD cases born to mothers
with autoimmune diseases and 952,211 controls. Of them,
six studies reported a positive association while four did not
reveal a substantially significant association. While evaluating
the entire cohort they found that children of mothers
with autoimmune diseases during pregnancy had a 30%
greater risk of ASD. A positive association was identified
between maternal autoimmune thyroid disease and ASD in
the offspring. No significant difference was found for maternal
SLE, inflammatory bowel disease, idiopathic thrombocytopenic
purpura (ITP), psoriasis. and rheumatoid arthritis (Chen et al.,
2016).
Wu et al evaluated the relationship between family history
of autoimmune diseases and risk of ASD in children by a
meta-analysis of 11 articles, including 3 cohort studies, 6 case-
control studies. and 2 cross-sectional studies published up to
Dec 2014. They found in the pooled analysis that family history
of all autoimmune diseases combined was associated with a
28% higher risk of autism. Maternal autoimmune diseases were
not associated with childhood autism and significant relative
risks were only found in case-control studies. Type 1 diabetes
in either of the parents, family history of rheumatoid arthritis,
hypothyroidism, and psoriasis were significantly associated with
higher risk of ASD in children (Wu et al., 2015).
In summary: there is insufficient data to associate maternal
autoimmune diseases with increased rate of ASD. However,
autoimmune diseases with specific IgG antibodies like TPO-
Ab, or anti-β2GP1 that cross the placenta seem to increase
significantly the rate of ASD in the offspring
Pre-Eclampsia
Preeclampsia may trigger aberrant neurodevelopment through
placental, maternal, and fetal pathophysiologic mechanisms.
Preeclampsia results from shallow placentation that may lead
to fetal hypoperfusion. Association between pre-eclampsia and
ASD was offered when brain MRI of 7–10 years old children (5
boys and 5 girls), offspring of pre-eclamptic pregnancies, revealed
enlarged brain regional volumes in the cerebellum, temporal
lobe, brain stem, and right and left amygdalae. These offspring
also displayed reduced cerebral vessel radii in the occipital and
parietal lobes. Enlarged left and right amygdalae were described
in ASD and temporal lobe epilepsy (Ratsep et al., 2016).
Recent cohort studies suggested an association between pre-
eclampsia and ASD. In the Swedish, population-based, case-
control study that included 1216 subjects with autism who were
born between 1987 and 2002 and 6080 controls, preeclampsia
was associated with 50% increased risk of an autism spectrum
disorder (Buchmayer et al., 2009). A recent study from the
California Department of Developmental Services that compared
517 ASD cases to 350 controls found that pre-eclampsia
complicated the pregnancy of children with ASDmore than twice
as often as those of controls and the association was more robust
in those pregnancies complicated by severe disease (Walker
et al., 2015). Two cohort data showed increased prevalence of
ASD among pre-eclamptic pregnancies. Analysis of 87,677 births
between 1996 and 2002, of the South CarolinaMedicaid program,
found greater odds of ASD with (OR = 1.69) or without (OR =
1.85) controlling for birth weight (Mann et al., 2010). Analysis
of 218,890 singleton live births in Alberta, Canada, between 1998
and 2004 also found greater odds of ASD (OR = 1.49; Burstyn
et al., 2010). Compared to these studies there was no association
between pre-eclampsia and ASD among 28,967 children born
between 1995 and 2008 in Aberdeen city and district (Love
et al., 2012). A meta-analysis of 85 studies of pre-, peri,- and
neonatal hazards related to PDD, including autism, concluded
that there was not enough data in order to determine risk for
PDD (Guinchat et al., 2012).
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In conclusion: Preeclampsia seems to be an additional risk
factor for ASD, but more studies are needed for the conclusive
confirmation of such an association.
THE INFLAMMATORY AND INFECTIOUS
ORIGIN OF ASD
Adverse intrauterine environment resulting from maternal
bacterial and viral infections during pregnancy represent a
significant risk factor for several neuropsychiatric disorders
including ASD (Adams Waldorf and McAdams, 2013). The
association between intrauterine inflammation, infection and
ASD is based on both epidemiological studies and case reports.
Many studies associate maternal infection with ASD, and
some studies even found that the season or month of birth was
significantly related to the risk of ASD. For example, Gardener
et al. (2011) found in ameta-analysis thatMarch andAugust were
both suggested as birth months associated with an elevated risk
of ASD and hypothesized that a relationship may be caused by
seasonal variation in viral or other infections.
Epidemiological Population Studies
An increased rate of ASD was found among children born
to mothers that were hospitalized due to infection during
pregnancy. Atladottir et al. (2010) matched the Danish Medical
Birth Register of children born between 1980 and 2005, the
Danish National Hospital Register and the cohort data in the
Danish Psychiatric Central Register (1,612,342 children with
10,133 cases of ASD). They found that admission to hospital due
to maternal viral infection in the first trimester of pregnancy
increased the adjusted hazard ratio for ASD in the offspring
by 2.98, and due to maternal bacterial infection in the second
trimester by 1.42. No specific infectious category was associated
with ASD in the offspring. Later, these authors (Atladottir et al.,
2012) evaluated in the Danish cohort the association between
self-reported maternal common infections and ASD among
children born between years 1997–2003, and found that infection
with influenza resulted in a hazard ratio of 2.3.
Lee et al. (2015) investigated the Swedish nationwide register-
based birth cohort of children born in Sweden in 1984–2007
and followed until December 31, 2011. They found that 3.7%
of ASD cases and 2.6% of non-ASD cases had mothers that
were hospitalized with a diagnosis of infection during pregnancy.
Maternal inpatient diagnosis of infection during pregnancy was
associated with increased OR of ASD regardless of whether the
infection was bacterial, viral, or other/unknown. The higher risk
of ASD was observed during all trimesters: the 1st trimester
(OR = 1.24), 2nd trimester (OR = 1.38), and 3rd trimester
(OR = 1.36). In a subsample of the total Swedish population,
the Stockholm Youth Cohort, the odds ratio for ASD with
intellectual disability was 1.50, not related to the type of infection.
Contradictory to these findings, Dodds et al. (2011) found that
maternal infection during pregnancy did not increase the rate of
ASD.
In a meta-analysis of 40 papers published until 2007 Gardener
et al. (2009) evaluated the relationships between autism and
pregnancy-related factors. Combined together there was no
statistical increase in ASD except for maternal rubella with
an OR of 1.66. However, when the analysis was limited to
the four studies that controlled for multiple covariates or used
sibling controls exposure to intra-uterine infections, a significant
increase in risk for autism in OR was observed: 1.82 (1.01–3.30).
Case control studies comparing complications of pregnancy
including maternal infection have also shown an association
between viral maternal infections and ASD (Wilkerson et al.,
2002). A similar association was found in women hospitalized
during pregnancy due to bacterial infection (Zerbo et al., 2013).
There were, however, case control studies that did not find
any association of ASD with either maternal viral or bacterial
infections (Langridge et al., 2013).
In summary: many but not all population or case control
studies have shown a slight to moderate association of maternal
infections with ASD. The controversy might be related to the
fact that only several specific maternal infections (subgroups of
women with infection during pregnancy) are associated with
ASD. These are mainly Rubella, CMV and possibly influenza.
Congenital Rubella
The association between Rubella and ASD is based on few
population studies and case reports. Berger et al. (2011)
calculated that the rubella vaccination prevented an estimated
number of congenital rubella cases that ranged from 8300 to
62,250 and that the corresponding ASD prevention estimates
ranged from 614 to 4607 cases, depending on the infectious rate
and prevalence of ASD among offspring of infected mothers. We
should remember that at the time of the rubella epidemics, ASD
definition was not the same as nowadays.
The largest study associating congenital rubella with ASD
was reported in 1978 by Chess et al. (1978) who evaluated
243 children with congenital rubella, most of them followed
until 9 years. Eighteen (7.4%) had autism compared to expected
0.07 (0.35/1000) in the general population at that time. All the
children with autism also had other rubella associated anomalies
including cardiac, neurologic, hearing and visual problems.
Desmond et al. (1978) reported behavioral disturbances among
45% of 29 non-retarded children with congenital rubella at the
age of 9–12 years. Carvill et al. (Carvill and Marston, 2002)
described 12 young males with congenital Rubella who suffered
from sensory imbalance and ASD. Associated morbidities
included: visual and hearing impairment and seizures in three.
Feldman et al. (1973) evaluated 12 children with autism or
autistic traits and compared them with 25 children with a variety
of psychiatric diagnoses, 21 children with language delay and 26
normal controls. None had a history of rubella. Sero-positivity for
rubella was found to be significantly higher among the children
with language delay, 8/21 and among children with autism, 3/12
compared to the other groups and the general population. All
the mothers of the sero-positive children were sero-positive for
rubella as well. Other reported cases of congenital rubella also
described ASD children who suffered from hearing and visual
impairment, iris hypoplasia, heart malformations, retinopathy,
and seizures (Assumpcao and Kuczynski, 2002; Hwang and
Chen, 2010).
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CMV
The diagnosis of maternal CMV is based on medical history,
serological studies for CMV or late diagnosis by preserved blood,
mostly from Guthrie cards or dried umbilical cord. Koyano et al.
(2004) and Sakamoto et al. (2015) used dried umbilical cords
for retrospective diagnosis of congenital CMV infection in Japan
where obstetric hospitals customarily provide dried umbilical
cord to every parent as a symbol of the bond between mother
and child.
Yamashita et al. studied seven children with congenital CMV,
two of them had ASD. Neuroimaging studies did not vary
between those who developed or did not develop autism when
seven infants with congenital CMV were evaluated. Three had
sub-ependymal cysts and two had calcifications. All had mental
retardation (Yamashita et al., 2003).
When children with ASD were assessed, those seropositive
for CMV tended to test worse in the major severity scales
than the seronegative ones (Gentile et al., 2014). Additionally,
Yamazaki et al. found that ASD cases with cochlear implants
had lower language and social function than other children with
corresponding developmental quotients (Yamazaki et al., 2012).
Some studies showed that CMV DNA was detected among ASD
cases in a higher prevalence than in the general population;
however the numbers were small: 2/27 by Sakamoto et al.
compared to incidence of ASD in Nagasaki which was 0.31%,
p = 0.004 (Sakamoto et al., 2015); 3/76 by Stubbs et al. even
though two had multifactorial prenatal causes for autism (Stubbs
et al., 1984); 4/26 by Engman et al. with two of them also having
cerebral cortical malformations (Engman et al., 2010). Townsend
et al. (2013) evaluated 176 infants with congenital CMV born
in Sweden and the United Kingdom between 1977 and 1986,
and followed them until at least 5 years; none was diagnosed
with ASD.
The role of individual placentas in the protection of the fetus
against congenital CMV infection is exemplified by the different
outcome in association with CMV stigmata, as described by
Kitajima (Kitajima et al., 2012) in a triamniotic- trichorionic
triplet born at 31 weeks after maternal febrile illness at 24
weeks. Two girls were asymptomatic; the third, a boy, had
lower birth weight, increased IGM titer, thrombocytopenia,
hepatosplenomegaly, retinitis, brain calcifications, and suffered
from ASD. The triamniotic- trichorionic placentas had no fusion
or structural abnormalities. Examination of the placenta of the
third-born triplet showed that it was paler than the other two and
had more severe villitis.
Other reported cases of ASD and congenital CMV also
had associated anomalies including brain calcifications and
chorioretinitis (Stubbs, 1978; Stubbs et al., 1984; Ivarsson et al.,
1990; Sweeten et al., 2004; Lopez-Pison et al., 2005; Ikeda et al.,
2006; Kawatani et al., 2010; Dogan et al., 2011).
In summary: There seem to be sufficient studies to associate
maternal CMV infection in pregnancy to an increased rate of
ASD in the offspring, especially in the children who suffer from
other brain manifestations of congenital CMV.
Influenza
Studies associating maternal influenza and ASD are based on
maternal reports. As stated above, Atladottir et al. (2012) found
self-reported maternal infection with influenza to be associated
with increased risk for infantile autism (adjusted HR: 2.3 [95%
CI: 1.0–5.3]). The highest association was found with prolonged
episodes of fever.
Zerbo et al. (2013) in a telephone interview, evaluated cases
and controls in the Childhood Autism Risk from Genetics and
Environment (CHARGE) Study. While comparing data from
538 children with ASD and 421 normal controls in association
with maternal influenza during pregnancy, they found that the
weighted odds ratio (wOR) between mothers of ASD children
and those of children with normal development was 1.26.
When they analyzed the association between fever and ASD,
the odds ratio for mothers of children with ASD and fever
during pregnancy doubled that of mothers of normal controls
(wOR = 2.12). They also found that the wOR for ASD was
2.55, for children whose mothers reported fever but did not take
anti-pyretic medication. For women who reported fever and took
anti-pyretic medications, the wOR for ASDwas only 1.30. Hence,
if there is an association, it is weak, and apparently due to fever.
Inflammation
Maternal immune activation and cytokine dysregulation was
also shown to be a mediator in the neuro-pathological behavior
observed in autism.Maternal immune system and animal models
were used to evaluate the role of cytokines in brain dysregulation
together with in-vitro studies that evaluated the association
between inflammatory mediators and neurological components.
Studies Evaluating Maternal Immune System
Increased levels of inflammatory mediators obtained from stored
samples were found in large population studies. Abdallah et al.
(2012, 2013) used a pool of samples from more than 100,000
pregnant women in Denmark and had their biologic samples
stored from 1980 to 2004, and matched 421 singleton ASD
cases born between 1982 and 2000 for gender and birth year
with 820 controls. Levels of Monocyte Chemotactic Protein-
1 (MCP-1) which play a role in the maturation of cerebellar
Purkinje cells and may serve as a useful marker of abnormal
neuronal development, were significantly elevated among ASD
cases compared to controls. Using the same cohort amniotic fluid
they found that samples from 331 ASD cases compared to 698
controls, had significantly elevated levels of IL-4, IL-10, TNF-
α, and TNF- β. Goines et al. (2011) also found Increased levels
of IL-4, IL-5, and IFN-gamma in banked serum collected from
women at 15–19 weeks of gestation who gave birth to a child
ultimately diagnosed with ASD (n = 84). Grether et al. (2010)
found by examining screening filter paper blood specimens from
the California Genetic Disease Screening Program of 213 ASD
cases and 265 controls that children with ASD had lower total
IgG and that the median value, for Herpes Simplex type 1Virus
IgG was significantly lower compared to controls.
Braunschweig et al. (2008) found reactivity to two protein
bands against fetal brain at approximately 73kDa and 37kDa in
plasma from 7 of 61 (11.5%) mothers of children with autism.
These bands were not found in controls. These children also
showed behavioral regression. It is assumed that the presence of
specific anti-fetal brain antibodies in the circulation of mothers
during pregnancy is a potential trigger to induce a downstream
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effect on neurodevelopment that may lead to autism. Mazina
et al. (2015) investigated the gene-environment interaction
by evaluating the interactive effects of maternal infection in
pregnancy and the presence of copy number variants which are
considered likely to play a contributing role in symptoms of ASD.
Participants included 1971 children with ASD between the ages
of 4 and 18 years with complete genetic, maternal pregnancy
history, and phenotypic information. A statistically significant
interactive effect of the presence of copy number variants and
maternal infection on autistic symptomatology was observed.
C reactive protein (CRP) is an inflammatory marker that
rises in response to infection or inflammation. Analysis of early
gestational CRP levels in maternal sera and childhood autism
in the Finish birth cohort (consisting of 1.2 million births from
1987–2007) revealed that increased maternal CRP levels were
significantly associated with autism in the offspring (OR= 1.12).
The increased risk was found in both sexes (Brown et al., 2014).
Contradictory to these results, no association between maternal
CRP blood levels during the first trimester of pregnancy and ASD
in their offspring (children evaluated at 6 years) was found among
4165 pregnant women in Rotterdam that gave birth between 2002
and 2006 (Koks et al., 2016).
In Conclusion
In children affected by intrauterine infections with rubella or
CMV, the association with ASD seems to result from the insult to
the nervous system, as all also had other neurological problems
as well as visual and hearing impairment, suggesting that ASD
is secondary to the primary morbidity. Large population studies
did not find a specific maternal infection to be associated with
ASD, implying that the association between maternal infection
during pregnancy and ASD is apparently related to maternal
inflammatory process; hence, maternal immune activation may
play a role in neuro-developmental perturbation.
EXPOSURE TO DRUGS AND CHEMICALS
DURING PREGNANCY AND ASD IN THE
OFFSPRING
Several drugs and chemicals have been associated with an
increased rate of ASD following intrauterine exposure. However,
the association was clearly demonstrated only in few drugs. In
others, there are either few reports, or the existing literature is
contradictory.
Exposure to SSRI’s
Selective serotonin reuptake inhibitors (SSRIs) are among the
most used drugs for the treatment of depression especially
during pregnancy (Evans et al., 2001; Pereira et al., 2009). They
increase extracellular serotonin and are recommended for first-
line pharmacological management of depression because they
are considered safer and better tolerated than other types of
antidepressants. SSRIs and other antidepressant medications
cross the placenta and are secreted in breast milk, thus raising
concerns about possible adverse effects from fetal and infant
exposure. Several studies show a possible association between
SSRIs exposure during pregnancy and a higher risk of ASD in
children (Croen et al., 2011b; Rai et al., 2013; Gidaya et al.,
2014; Harrington et al., 2014). Three out of six recently published
case–control studies reported a significantly positive association
between SSRI exposure during pregnancy and ASD in children.
Odds ratio in the different studies ranged from 2.2 (Croen et al.,
2011b) with the strongest effect associated with treatment during
the first trimester of pregnancy (OR, 3.8)—to 2.34 (Rai et al.,
2013) and the highest was 2.91(Harrington et al., 2014). They
found that the strongest association was following exposure in
the first trimester of pregnancy. In addition, Gidaya et al. (2014)
studied in Denmark a group of 5215 children diagnosed with
ASD and 52,150 controls, all born between 1997 and 2006. The
OR for ASD doubled among the children born to mothers who
used SSRIs at any time during pregnancy.
Recently published large population based retrospective study
by Boukhris et al. (2016) reported a significant association
between maternal use of SSRI’s during pregnancy and the risk
of ASD in children. The study included 145,456 children born
in Quebec, Canada from 1998 to 2009, of which1054 (0.72%)
had at least one diagnosis of ASD. The authors reported that
use of antidepressants during the second and/or third trimester
was associated with the risk of ASD (31 exposed infants; adjusted
hazard ratio, 1.87; 95% CI, 1.15–3.04). Stronger association was
found if the mother used SSRI’s antidepressants (22 exposed
infants; adjusted hazard ratio, 2.17; 95% CI, 1.20–3.93) or used
more than one class of antidepressants (5 exposed infants;
adjusted HR, 4.39; 95% CI, 1.44–13.32). The risk was persistent
even after taking into account maternal history of depression
(29 exposed infants; adjusted hazard ratio, 1.75; 95% CI, 1.03–
2.97). The use of other antidepressants during the first trimester
or the year before pregnancy was not associated with the risk
of ASD.
In contrast to these studies, Hviid et al. (2013) found no
connection between the use of SSRIs during pregnancy and the
increased risk for ASD (OR, 1.20; 95%CI, 0.90–1.61). Similarly,
Sorensen et al. (2013) found that children who were exposed
to SSRIs during pregnancy have indeed a 50% higher risk for
ASD compared with unexposed children, but after controlling
for important confounding factors such as maternal history of
affective disorder and familial risk factors, they did not detect
any significant association between maternal use of SSRI’s during
pregnancy and ASD in the offspring. Both researchers used data
from the Danish civil registration system and Danish health
registry systems about children who were born in Denmark
between 1.1.96 and 31.12.2005 (Hviid) and until 31.12.2006
(Sorensen). The latest cohort study by Malm et al. from Finland
(Malm et al., 2016) examined the rate of ASD among the
offspring of 15,729 pregnant women exposed to SSRIs during
pregnancy compared to 9651 women with psychiatric disease
but no antidepressant treatment and 31,394 non-exposed women
and without psychiatric disease. They did not find any increase
in the rate of ASD among the SSRIs exposed children, as the
rates of ASD were similar to the rate observed in the offspring
of mothers with a psychiatric disorder but without treatment.
The main finding in this study was an increase in the rate of
depression in the SSRI exposed children at adolescence.
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In summary: It is still unclear whether there is a direct
association between the use of SSRIs during pregnancy and
increased rate of ASD in the offspring. Alongside studies which
show an association with ASD there are also negative studies. Of
special importance is the recent negative study by Malm et al.
(2016) as it examined the largest population of SSRI exposed
children and adequately adjusted for confounders. It seems more
reasonable that maternal depression itself, which is expressed by
the use of antidepressants, or other causes, might be responsible
for the association. Medical treatment during pregnancy of
women with depression should apparently continue in spite of
these, rather conflicting studies.
Exposure to Paracetamol
Several studies suggested a possible association betweenmaternal
use of paracetamol during pregnancy and a higher risk of
ASD among the children. Bauer et al. (Bauer and Kriebel,
2013) examined the association between maternal paracetamol
usage or early life paracetamol exposure in males and the
prevalence of ASD. They reported positive correlations between
ASD prevalence and indicators of both prenatal (r = 0.80)
and very early life (r = 0.98) paracetamol exposures. Liew
et al. (2015) followed 64,322 children and mothers enrolled in
the Danish National Birth Cohort. They reported that maternal
use of paracetamol in pregnancy was associated with ASD with
hyperkinetic symptoms only (HR = 1.51 95% CI 1.19–1.92), but
not with other types of ASD (HR = 1.06 95% CI 0.92–1.24). More
than half of pregnant women in the USA and Europe report
using paracetamol and it is the most common drug administered
to children; as a result it is difficult to connect between these
exposure and ASD). It is obvious that the data is insufficient to
draw any conclusion from these studies.
Exposure to β2-Adrenergic Receptor
Agonists
Connors et al. (2005) was the first to examine the effects
of prenatal overstimulation of the beta2-adrenergic receptor
(B2AR), in 37 dizygotic pair of ASD twins who were exposed
to terbutaline, a B2AR agonists, commonly prescribed to treat
asthma and other pulmonary disorders and to delay preterm
labors. They found increased concordance for autism spectrum
disorders in dizygotic twins (relative risk = 2.0), with a further
increase in the risk for male twins with no other affected
siblings (relative risk = 4.4) related to terbutaline exposure
overall.
Croen et al. (2011a) examined maternal use of B2AR agonists
during pregnancy among 291 children with and 284 without
ASD. No evidence linking B2AR exposure during pregnancy with
ASD risk was found. However, they reported that exposure to
terbutaline only during the third trimester for more than 2 days
may be associated with an increased risk of ASD.
A new case control study by Gidaya et al. (2016) investigated
the associations between prenatal use of B2AR agonist drugs
and the risk for ASD. They studied 5200 ASD diagnosed cases
and 52,000 controls from the Denmark’s health and population
register. The frequency of B2AR agonist drug exposure in
pregnancy was 3.7% (190) for cases and 2.9% (1489) in
controls. B2AR agonist use during pregnancy was associated
with increased risk of ASD, even after adjustment for maternal
asthma and other covariates (OR: 1.3, 95% CI: 1.1–1.5). There
was no difference regarding the trimesters of pregnancy during
exposure.
Exposure to Valproic Acid
Antiepileptic drugs are among the most common teratogens
prescribed to women of childbearing age, especially as some
of them are also used for psychiatric indications and pain
management. Prenatal exposure to antiepileptic drugs (AEDs)
is associated with an increased risk of major congenital
malformations and delayed cognitive development among the
offspring, in a dose dependent manner (Meador et al., 2007;
Tomson et al., 2011). Valporic acid (VPA), apparently the most
teratogenic AED (Werler et al., 2011), was also found to be
associated with impaired cognitive outcomes (Meador et al.,
2009). Many reports demonstrate that prenatal exposure to VPA
is also associated with a high risk for ASD in the prenatally
exposed child in addition to other neurodevelopmental disorders,
especially in language development (Moore et al., 2000; Williams
et al., 2001; Rasalam et al., 2005; Bromley et al., 2008).
Christianson et al. (1994) were apparently the first to point to
of a possible association between intrauterine exposure to VPA
and ASD, as observed in four children exposed to VPA during
pregnancy. All children had developmental delay and one of
them had ASD.
Several years later, Williams et al. (2001) examined five
children with ASD and found that VPA was used during
pregnancy in all five, but in three in combination with another
anticonvulsant. Moore et al. (2000) found among 57 children
affected by antiepileptic drugs that four had autistic syndrome
and two had Asperger syndrome. Five of them (10.8% of 46
exposed to VPA) were exposed to VPA alone or combined
with another AED. Rasalam et al. (2005) evaluated the clinical
features and frequency of autistic disorder or Asperger syndrome
in 260 children exposed to anticonvulsant medication during
pregnancy, by using the DSM IV criteria. They found that VPA
was the drug most commonly associated with autistic disorder.
The prevalence of ASD in children exposed to VPA alone was
8.9 and 11.7%, among children exposed to sodium valproate in
combination with other AEDs. Bromley et al. (2008) examined
296 children of epileptic mothers and 336 children born to
mothers without epilepsy. Out of the 632 children from both
groups 10 have been diagnosed with ASD, 7 of them were
exposed to AEDs. Of those seven children, four were exposed to
VPA monotherapy (4/64 6.3%). In addition to these prospective
studies, several large retrospective studies have also supported the
findings that in uteroVPA exposuremay be linked to an increased
risk of ASD (Ornoy, 2009).
Christensen et al. (2013) in a much larger Danish population-
based study reviewed the National Population Register with
prescription data, psychiatric register and birth records. Records
were collated for 655,615 eligible children, with 508 exposed to
VPA and 2136 to other anticonvulsants. An increased risk of
ASD (Hazard Ratio-HR = 2.9, 95% CI, 1.7–4.9) was found in
children exposed to VPA during pregnancy. The risk of ASD was
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elevated compared to non-exposure when VPA was taken in the
first trimester of pregnancy or after the first trimester.
Animal models in rodents using different neurobehavioral
measures fully support the human data. Exposure of mice and
rats to VPA produced autism-like behaviors in the offspring
(Schneider and Przewlocki, 2005; Wagner et al., 2006). Maternal
exposure to VPA induced developmental delay, lifelong deficits in
social behavior as well as motor deficits, anxiety-like behavior and
alterations in postnatal growth and development in the offspring
(Schneider and Przewlocki, 2005; Kolozsi et al., 2009; Bambini-
Junior et al., 2011). As in humans, anatomical alterations such as
reduced number of cerebellar Purkinje cells, damage to cranial
nerve nuclei have been described (Rodier et al., 1997; Ingram
et al., 2000) as well as enhanced synaptic plasticity of the
prefrontal cortex (Sui and Chen, 2012).
In summary: VPA seems to be the drug with the highest
association to ASD as proven in human and animal models and
should therefore not be used as a first-line antiepileptic drug in
pregnant women or in those who plan pregnancy. Similarly, it
should not be used as a mood stabilizer for the treatment of
psychiatric patients.
Exposure to Thalidomide
Thalidomide is a well-known human teratogen that caused
multiple birth defects including limb reduction defects, ocular
and cardiovascular anomalies. Thalidomide is still used in
the treatment of leprosy and multiple myeloma (Ito et al.,
2010). Stromland et al. (1994) have reported increased number
of incidences of autism in children exposed prenatally to
thalidomide. At least four of the 100 thalidomide embryopathy
patients met full criteria for DSM III R autistic disorder- much
higher prevalence then in the general population. The critical
window of exposure to thalidomide was in the first trimester,
mainly days 20–35 post fertilization. Because thalidomide is
generally used in elder patients, no newer data was published
regarding this possible effect, making it difficult to accept or deny
this possible association, or to calculate the relative risk.
Exposure to Cocaine
Cocaine use during pregnancy has many deleterious effects on
both the mother and the fetus, (Singer et al., 1993; Fox, 1994).
Cocaine, which is used nowadays mainly as a recreational drug
crosses the placenta and the fetal blood-brain barrier readily, and
may affect the fetal central nervous system (Roe et al., 1990). Its
use during pregnancy may have a variety of deleterious effects
on the fetus including preterm delivery, intrauterine growth
retardation, placental abruption, stillbirth, and neonatal death
(Singer et al., 1993; Fox, 1994). Several studies reported a possible
association between the use of cocaine during pregnancy and the
development of ASD in the offspring.
Davis et al. (1992) examined 70 children with a history of
prenatal cocaine exposure, in Harlem, New-York and found that
nine of the children met the DMS III R criteria for autistic
disorder—11.4%, much higher than the national average at that
time. Harris et al. (1995) examined three, 25–36 month old
children with prenatal exposure to cocaine, alcohol and other
illicit drugs. They reported that all three children showed a
notable pattern of autistic-like behaviors.
We could not find other studies associating prenatal cocaine
exposure with ASD. Hence, judging from the paucity of studies,
in spite of relatively high use, there seems to be insufficient data
to support such association. Hence, the relative risk could not be
calculated.
Exposure to Ethanol
Fetal alcohol syndrome (FAS) is a pattern of physical and
neurodevelopmental abnormalities which develop in some of
the children who were exposed to high levels of alcohol during
pregnancy. It is characterized by prenatal and postnatal growth
deficiency, CNS dysfunction including mental retardation and
behavioral abnormalities, a distinctive pattern of facial features
and major malformations of several organs. Some studies have
shown a connection between FAS and an increased risk of ASD.
Nanson (1992) described six children aged 6–15 years, out
of a data base of 326 FAS individuals who showed the physical
phenotype of FAS and also presented a behavioral phenotype
typical of autism spectrum disorder. The children also suffered
from significant retardation of their cognitive and social skills.
These data is representing an incidence of ASD in 1 of 54 cases
of FAS.
Aronson et al. (1997) found that among 24 children born
to mothers who used high doses of alcohol during pregnancy,
two had Asperger syndrome and one had autistic-like behavior.
There was a clear correlation between the occurrence and severity
of ASD and the degree of alcohol exposure in utero. Landgren
et al. (2010) assessed 71 children adopted from Eastern Europe
between 4.8 and 10.5 years of age and found fetal alcohol
syndrome in 37 of the children (52%) and autism in 6 of the
children (9%), suggesting a positive association between prenatal
alcohol consumption and ASD.
The association between maternal alcohol consumption in
pregnancy and ASD does not seem to exist with low alcohol
intake. In a large population-based cohort study Eliasen et al.
(2010) evaluated a total of 80,522 mother-child pairs. Almost
half of the women reported an average weekly intake of at least
half a standard alcoholic drink (45%), and approximately one-
quarter of the women reported at least one episode of binge
drinking during pregnancy. They found no positive associations
between ASD and average alcohol consumption or number of
binge drinking episodes during pregnancy Adjusted hazard ratio
for alcohol consumption of 0.5–1.5 glasses of wine per week (119
cases) = 0.84, 95% CI: 0.68–1.05; adjusted hazard ratio for single
binge drinking episode (51 cases) = 0.72, 95% CI: 0.53–0.97.
In summary: Although the existing data of the association
between high amounts of alcohol consumption in pregnancy and
the risk for ASD in children (especially those with FAS) is well
established, the relation to lower amounts ingested is not yet
established.
Exposure to Misoprostol and Moebius
Sequence
Misoprostol is a prostaglandin analog drug widely used to
induce medical abortions (Gonzalez et al., 1998). It is also often
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prescribed for the prevention and treatment of gastric ulcers.
Möbius sequence is a rare congenital disorder, characterized by
uni-or bilateral eye-face palsy due to damage to cranial nerve
nuclei, associated with muscle or skeletal malformations in the
upper or lower limbs, with an estimated prevalence of 1:50,000
cases in the general population (Stromland et al., 2002; Verzijl
et al., 2003). Among the etiological factors responsible forMöbius
sequence, apart from genetic causes, is also intrauterine exposure
to teratogens mainly misoprostol (Bandim et al., 2003; Vauzelle
et al., 2013). Judging from the literature, it is expected that about
1% of children exposed in utero to misoprostol will have Möbius
sequence (Gonzalez et al., 1993; Marques-Dias et al., 2003).
Johansson et al. (2001)analyzed 25 Swedish individuals with
Möbius sequence. Six patients met all diagnostic DSM III R
criteria for autism which is a much higher frequency than
that of the general population. These findings suggest a strong
association between Möbius sequence and ASD. All these
patients also had mental retardation.
Bandim et al. (2003) examined 23 Brazilian patients with the
age range of 1–11 years, which had been diagnosed as having
Möbius sequence based on clinical findings. They identified seven
children with ASD of whom four (57.1%) had a positive history
of prenatal exposure to misoprostol during the first trimester of
pregnancy. They concluded that the prevalence of ASD found in
Möbius patients is around 26.1%, much higher than the general
population, thus suggesting a strong association linking the two
pathologies.
The correlation between misoprostol exposure during
pregnancy and ASD is suggested on the basis of reports
published in the literature. However, since most, if not all
affected children also had Mobius syndrome, it is difficult to
directly associate misoprostol exposure to ASD. We found no
reports on an association of ASD to misoprostol exposure in
exposed children that do not present the symptoms of Moebius
syndrome. It should be remembered that the experimental
models of VPA—induced ASD in rats and mice have also caused
damage to the cranial nerve nuclei, similar to the damage
observed in Mobius syndrome (Rodier et al., 1997; Ingram et al.,
2000; Sui and Chen, 2012). Hence, it is possible that the relation
of misoprostol—induced Mobius syndrome to ASD is not a
result of the direct effects of misoprostol but rather from the
damage to the cranial nerve nuclei.
Folic Acid Deficiency
Folic acid deficiency is associated with a variety of adverse
outcomes in the offspring, especially Neural TubeDefects (NTD).
Folic acid deficiency was therefore also proposed as a possible risk
factor for ASD.
Schmidt et al. were the first to report that mothers of children
with autism were less likely, than those of typically developing
children, to report having taken prenatal vitamins, including folic
acid, during the 3 months before pregnancy or the first month
of pregnancy (OR, 0.62; 95% CI, 0.42–0.93). Later, Schmidt
et al. (2012) examined the effect of maternal folic acid intake
on the ASD risk in a group of 429 children with ASD and 278
normal children and found thatmothers of normal children had a
significantly greater mean folic acid intake during the first month
of pregnancy compared to mothers of children with ASD. A
mean daily folic acid intake of ≥600µg during the first month
of pregnancy was associated with reduced ASD risk (OR, 0.62),
and risk estimates decreased with increased folic acid (P-trend=
0.001). The association between folic acid and reduced ASD risk
was strongest for mothers and children with MTHFR 677 C > T
variant genotypes.
In a prospective Norwegian cohort study, Surén et al. (2013)
followed up 85,176 children of whom 270 had been diagnosed
with ASD and found a significantly higher rate of Autism in
children who were not exposed in utero to folic acid (0.21%)
compared to children of mothers who took 400µg or more folic
acid (0.10%) during a month before and 2 month after the start
of pregnancy (OR, 0.6).
Recently, DeVilbiss et al. (2015) summarized the existing
literature regarding folic acid deficiency and ASD and discussed
the limitations of the different studies. He concluded that the data
associating Folate deficiency with a higher risk of autism is yet
inconclusive. Hence, it is obvious that more studies are needed to
elucidate the possible association of maternal folic acid deficiency
with ASD.
EXPOSURE TO HIGH LEVELS OF
ENVIRONMENTAL AGENTS
Exposure to Air Pollution
Increased air pollution is one of the more common signs of our
modern life, and its possible effects on health are extensively
investigated. In spite of great difficulties in measuring the extent
of air pollution and the elucidation the large number of possible
confounding factors, more and more studies are being published
associating heavy air pollution to ASD.
The first study was apparently conducted in San Francisco
Bay area in 2006 by Windham et al. (2006). They examined the
effects of prenatal exposure to 19 hazardous air pollutants in
284 children with ASD compared to 657 controls. Elevated risk
for ASD was found in adjusted analyses of the top quartile of
exposure to chlorinated solvents and heavy metals [95% CI, 1.1–
2.1]. In this study, however, the exposure was estimated 2 years
after birth when ASD diagnosis was established. Hence the effects
might be attributed to postnatal effects of these pollutants.
Kalkbrenner et al. (2010) examined prenatal exposure to
35 hazardous air pollutants in 383 children with ASD and
2829 control children with speech and language impairment.
They found that prenatal exposure to hazardous air pollutants
including methylene chloride (OR, 1.4; 95% CI, 0.7–2.5),
quinoline (OR, 1.4; 95% CI, 1.0–2.2), and styrene (OR, 1.8; 95%
CI, 1.0–3.1) were associated with a higher risk for ASD.
Volk et al. (2011) investigated the association between ASD
and proximity of residence to freeways and major roadways
during pregnancy and near the time of delivery, in a group of 304
children with ASD and 259 controls. They found that maternal
residence during the third trimester (OR, 2.22; 95% CI, 1.16–
4.42) and at the time of delivery (OR, 1.86; 95%CI, 1.04–3.45)
were more likely to be near a freeway (≤309m) for the ASD
children than for the controls. They also found (Volk et al.,
2013) in an additional study that, during gestation, children with
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ASD were more likely to live at residencies that had the highest
quartile of exposure to traffic-related air pollution (OR, 1.98;
95% CI, 1.20–3.31) compared with control children. Regional
exposure during pregnancy with nitrogen dioxide and particulate
matter<2.5 and 10µm in diameter (PM2.5 and PM10) were also
associated with autism.
Similarly, Becerra et al. (2013) studied the influence of
exposures to traffic-related air pollution during pregnancy on
the occurrence of ASD with controls matched by sex, birth year,
and gestational age. They found a small but significant 12–15%
relative increase, per interquartile range, in odds of autism for
ozone (OR, 1.12, 95% CI: 1.06–1.19; per 11.54-ppb increase) and
particulate matter ≤2.5µm when mutually adjusting for both
pollutants.
Roberts et al. (2013) estimated the association between levels
of hazardous air pollutants at the time and place of birth and ASD
in 325 children with ASD and 22,101 controls. Prenatal exposures
to the highest quintile of air pollutants, such as diesel, lead,
manganese, mercury, and methylene chloride, were significantly
associated with ASD, with odds ratios ranging from 1.5 (for
overall metals measure) to 2.0 (for diesel and mercury). For most
pollutants, associations were stronger for boys (279 cases) than
for girls (46 cases) suggesting a significant gender difference.
Raz et al. (2015a) examined the association between maternal
exposure to particulate matter (PM) air pollution during
pregnancy and the risk of ASD compared to controls. They
found that PM2.5 exposure during pregnancy was associated with
increased risk of ASD, with an adjusted odds ratio for ASD per
interquartile range of 1.57 (95% CI: 1.22, 2.03). The association
between ASD and PM2.5 was stronger for exposure during the
third trimester (OR, 1.42 per inter-quartile range increase in
PM2.5, 95% CI, 1.09–1.86).
In a recent, population based case–control study in
Pennsylvania, Talbott et al. (2015) found that living in areas
with higher ambient levels of styrene and chromium during
pregnancy and the first and second years of life is associated
with increased risk of ASD with borderline effects for polycyclic
aromatic hydrocarbons (PAHs) and methylene chloride.
In contrast to these studies mostly carried out in the United
States, showing a consistently positive association between
exposure to several air pollutants during pregnancy and diagnosis
of ASD, a much larger, recently published analysis of four
European population-based cohorts appears to contradict those
findings, reporting no associations between ASD and prenatal air
pollution exposure (Guxens et al., 2016).
This research compared between nitrogen oxides and various
sizes of particulate matter concentrations at the participants’
birth home addresses during pregnancy and the presence of
autistic traits, but not formal diagnoses of ASD, in more than
8000 children. No associations were found between the presence
of autistic traits and prenatal exposure to any of the air pollutants
(odds ratio = 0.94; 95% CI: 0.81, 1.10 per each 10-µg/m3
increase in NO2 pregnancy levels). The researchers explained
the contradictory findings by the fact that previous case–control
studies selected children with a diagnosis of ASD, whereas this
study examined children with autistic traits from population-
based birth/child cohorts. An alternative explanation could be the
possible differences in air pollution levels and sources.
It can therefore be concluded that air pollution might be a
contributing factor in the risk for ASD, but the data is as yet
inconclusive.
In summary: these case control studies suggest that there is a
positive association between maternal exposure to air pollution
during pregnancy and ASD in children, especially following
exposure in the third trimester. Although small PM may cross
the placenta, there might also be other factors in the air pollutants
that are associated and were not measured.
Exposure to Pesticides
Few studies have examined the effects of in utero exposure
to pesticides such as organophosphates and carbamates on the
neurobehavioral development and the risk of ASD in children.
Each study reported an association with ASD.
Roberts et al. (2007) examined the association between
maternal residence near agricultural pesticide applications
during key periods of gestation and ASD in children. They
reported that ASD risk was higher in children whose mothers
lived near agricultural applications of organochlorines during
the first trimester of pregnancy (OR 6.1) and decreased with
increasing distance from such fields.
Shelton et al. (2014) evaluated whether residential proximity
to agricultural areas and therefore increased exposures to
pesticides during pregnancy is associated with ASD. They found
that residence near organophosphates at some point during
gestation was associated with a 60% increased risk for ASD,
higher for third-trimester exposures (OR, 2.0), and second-
trimester chlorpyrifos applications (OR, 3.3). Also, children of
mothers residing near pyrethroid insecticide applications just
before conception or during the third trimester were at greater
risk for ASD with ORs ranging from 1.7 to 2.0. We can
summarize that due to the paucity of studies in spite of extensive
use, an association between ASD and pesticides is plausible, but
it was not yet established.
Exposure to Heavy Metals
Maternal exposure to heavy metals, such as mercury, lead,
and cadmium, has been suggested to be associated with
neurodevelopmental disorders including mental retardation,
inattention, learning difficulties, and possibly ASD (Mendola
et al., 2002). Although there is more data on mercury, most
available data suggests that maternal exposure to mercury does
not play an important role in the development of ASD.Moreover,
several of the studies were carried out on the affected children
and not on their mothers, hence making the association with
pregnancy an unproven possibility (Kern et al., 2007). In that
respect we should add that Kern et al. (2007) found that
sulfhydryl reactive metals: arsenic, cadmium, and lead were
reduced in the hair of 45 children with ASD compared to
controls. They suggested that the children with ASD have a
problem in secreting these sulfhydryl reactive metals and their
accumulation may contribute to the symptoms of ASD.
Geier et al. (2009) examined the association between maternal
dental amalgams (containing 50% mercury) and the severity of
ASD diagnosis in a group of 100 autistic children. They found
that a rise in autism severity correlated with an elevation in the
number of dental amalgams in the mother during pregnancy.
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However, Yau et al. (2014) investigated the association between
ASD and levels of total mercury measured in maternal serum
from mid-pregnancy and infant blood shortly after birth in
84 children with ASD and 159 control children. They found
no significant associations between ASD and mercury levels in
maternal serum samples (OR, 0.96; 95% CI, 0.49–1.90) or in
newborn blood samples (OR, 1.18; 95% CI, 0.71–1.95).
Van Wijngaarden et al. (2013) examined prenatal exposure to
methyl mercury in 1784 children and young adults, by measuring
maternal hair samples collected at or near the time of birth.
They found no significant association between ASD and prenatal
methyl mercury exposure.
It can therefore be concluded that there in insufficient data to
associate prenatal exposure to heavy metals, especially mercury,
to a higher occurrence of ASD in the offspring.
Exposure to Cigarette Smoking
Heavymaternal cigarette smoking during pregnancy is associated
with an increased rate of spontaneous abortions, preterm
delivery, reduced birth weight, immune system difficulties such
as asthma and allergies and a relatively high rate of learning
disabilities and attention deficit disorders later in life (Castles
et al., 1999; Stene-Larsen et al., 2009; Kiechl-Kohlendorfer et al.,
2010). Several studies have examined whether prenatal exposure
to heavy tobacco smoke is also associated with ASD, and the
findings are inconsistent. Hultman et al. (2002) and Larsson
et al. (2009) found a mild association between smoking during
pregnancy and the risk of childhood autism (OR, 1.4 and 2.09,
respectively).
Kalkbrenner et al. (2012) assessed the association between
maternal smoking during pregnancy and ASD among 3315
children with ASD and 630,674 control children at 8 years of
age. A slightly positive association (OR 1.26) was found only for
“ASD not otherwise specified” (ASD-NOS), which disappeared
after correcting for possible confounding factors. Similarly Tran
et al. (2013) examined 4019 ASD cases and 16, 123 controls, in
a nested case-control study based on the Finnish Prenatal Study
of Autism (FIPS-A) and found no connection between maternal
smoking and childhood autism or Asperger syndrome, but found
a slight association with PDD (OR, 1.2, 95% CI, 1.0- 1.5).
Other large studies also did not find any association between
tobacco exposure and ASD. In a large registry based Swedish
case-control study, that included 3958 ASD cases and 38,983
controls, Lee et al. (2012) found that maternal smoking during
pregnancy is not associated with increased risk of ASD after
adjustments for parental education, occupation, and income.
Several additional studies (Maimburg and Vaeth, 2006;
Burstyn et al., 2010) and two recently published meta-analyses
by Rosen et al. (2015) and Tang et al. (2015), also reported
no significant association between maternal smoking during
pregnancy and ASD.
It can be summarized maternal smoking does not increase the
rate of ASD in the offspring.
CONCLUSIONS
The observed increase in the incidence of ASD in the last decades
is considered to result directly from changes in definitions and
better ascertainment. However, it is also possible that it reflects
a real increase in the occurrence of ASD. In addition to well-
defined genetic causes for ASD, examples of which we discussed
in this review, the current search for prenatal environmental
etiologic factors demonstrated real associations with a number
of causes that may affect the developing fetal brain raising the
vulnerability for ASD. Based on the findings reviewed here, we
may conclude—with caution—that: (1) A possible association
exists with maternal influenza in pregnancy, exposure to
pesticides and insecticides, exposure tomisoprostol, thalidomide,
cocaine, SSRIs, or folic acid deficiency. (2) A probable association
was found for maternal fever, autoimmune diseases, diabetes,
preeclampsia, and exposure to heavy air pollution. (3) A definite
association of ASD with maternal Rubella and CMV infections
in pregnancy, maternal inflammation and immune activation,
or exposure in pregnancy to VPA, and high levels of ethanol.
(4) Although sometimes suggested, there seems to be sufficient
evidence that there is no association with ASD for manymaternal
infections in pregnancy (i.e., herpes viruses, Epstein Barr virus,
varicella—zoster virus, parvovirus), smoking, exposure to heavy
metals or vitamin D deficiency.
Despite the increasing efforts in recent years, and
support from animal studies, we still seem to be in a stage
where the etiology of ASD is largely unknown and the
associations described in the literature are, for many agents,
inadequately proven. Hence, more research is needed to unravel
environmental contribution to the genetic etiology of ASD. This
type of research may ultimately lead to the establishment of
possibilities for prevention.
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